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Background: Pulmonary embolism (PE) is diagnosed with imaging techniques such as ventilation/perfusion
(V/P) lung scintigraphy or multidetector computed tomography of the pulmonary arteries (MDCT). Lung
scintigraphy can be performed with planar (V/P PLANAR) and tomographic (V/P SPECT) techniques. V/P
SPECT has higher sensitivity and specificity than V/P PLANAR. As nephrotoxic contrast media are not used
during V/P SPECT, examinations can be repeated for evaluation of resolution of perfusion defects after PE.
However, the value of residual perfusion defects identified using V/P SPECT for the prediction of recurrent
PE has not been thoroughly evaluated.
Material and methods:We evaluated resolution and recurrence of PE in 227patients (mean age 63±17 years,
134[59%] women) with PE undergoing ≥2 SPECT examinations in 2005–2007. PE was defined as minor
(b20% perfusion defect on SPECT, n=86), medium (20-50% perfusion defect on SPECT, n=99), or major
(>50% perfusion defect on SPECT, n=42).
Results: At second V/P SPECT examination, complete resolution of perfusion defects had occurred in 45 (52%)
patients with minor PE after 8.2±7.4 months, in 29 (29%) of patients with medium PE after 6.2±5.9 months,
and in 2(5%) of patients with major PE after 6.5±0.7 months. During 47±24 months of follow up, 37(16 %)
patients suffered recurrent PE. Of these 37, 34 (92%) showed residual perfusion defects at the second V/P
SPECT examination. Recurrence of PE was also predicted by advanced age and female gender. However,
in multivariate regression analysis, recurrence was only predicted by age (p=0.0013) and residual perfusion
defect on V/P SPECT (p=0.0039).
Conclusion: In conclusion, complete resolution of PE was common in patients with minor PE, whereas residual
perfusion defects were widespread in patients withmedium andmajor PE. PE patients identifiedwith persistent
perfusion defects at follow-up SPECT have a high risk of PE recurrence.© 2012 Elsevier Ltd. All rights reserved.Introduction
Pulmonary embolism (PE) is a common andpotentially fatal disorder
in which clinical symptoms and laboratory findings are non specific. A
firm diagnosis of PE can only be made by using imaging techniques
such as ventilation/perfusion (V/P) lung scintigraphy or multidetector
computed tomography of the pulmonary arteries (MDCT). Scintigraphy
with tomographic (V/P SPECT) technique has higher sensitivity and
specificity than with planar (V/P PLANAR) technique [1–3].The strength
of V/P SPECT is based on its sensitivity, specificity, and applicability to all
patients, regardless of age, kidney function or any other diseases [4].
Moreover, V/P SPECT confers a lower and predictable radiation burden
[5] particularly regarding absorbed breast doses [6,7]. Both V/P SPECT
and MDCT not only allow diagnosis of PE, but also enable visualisation
of other cardiopulmonary diseases [4].46 40 338097.
).
rights reserved.
he value of tomographic venti
b Res (2012), http://dx.doi.oHowever, the resolution of perfusion defects after a PE diagnosis is
insufficiently studied. Current recommendations for treatment duration
after PE [8,9] are also partly based on insufficient evidence. Patients
are usually treated with anticoagulants for 6 months, a therapy
conferringrisk of serious bleeding complications and inconvenience
because of the need for regular monitoring [9,10]. More individual
tailoring of anticoagulant treatment duration would be extremely
valuable in this patient group.
It would therefore be of great clinical value to have a safe investiga-
tional method which could be used in as many patients as possible, not
only for the diagnosis of PE, but also in routine follow-up after diagnosis
to visualise resolution of perfusion defects and to help in the prediction
of PE recurrence and the determination of treatment duration. Such
follow-up is not feasible with MDCT, however, as the method exposes
patients to substantial amount of radiation [11,12]and should therefore
not be used for routine follow-up. Moreover, MDCT does not allow quan-
tification of PE extension and has very low sensitivity in the diagnosis of
chronic PE [13–15]. V/P SPECT, on the other hand offers these possibilities.lation/perfusion scintigraphy (V/PSPECT) for follow-up and prediction
rg/10.1016/j.thromres.2012.09.002
Table 1
Baseline data in 227 patients with pulmonary embolism (PE) undergoing 2 examinations
with ventilation / perfusion (V/P) lung scintigraphywith tomographic (SPECT) technique,
and in subgroups of patients with minor (b20% perfusion defect on SPECT), medium
(20-50% perfusion defect on SPECT), or major (>50% perfusion defect on SPECT,)
PE.Mean±SD or n(%).
All patients,
n=227
Minor PE,
n=86
Medium PE,
n=99
Major PE,
n=42
Age (years) 63±17 59±20 64±17 70±11
Gender M/F 94/134 33/53 37/62 24/18
Prior VTE (n[%]) 50(22) 10(12) 31(31) 9(21)
Malignancy(n[%]) 51(22) 20(23) 20(20) 11(26)
Blood pressure
(BP, mmHg)
138±23/
80±13
137±20/
79±13
138±24/
81±13
141±24/
83±9
Prior surgery/
immobility
24 (11) 9 (10) 10 (10) 5 (12)
Autoimmune disease /
steroid therapy
35 (15) 11 (13) 20 (20) 4 (10)
Pregnancy/hormonal
therapy
15 (7) 5 (6) 7 (7) 3 (7)
Fig. 1. KaplanMeier curves showing recurrence of pulmonary embolism (PE) after second
examination with ventilation / perfusion (VP) lung scintigraphy with tomographic
(SPECT) technique in 227 patients with PE. The upper curve shows patients with residual
perfusion defects and the lower curve those without.
2 A. Alhadad et al. / Thrombosis Research xxx (2012) xxx–xxxThe aims of the study were to clarify patterns of resolution of perfu-
sion defects after PE, and whether residual perfusion defects on V/P
SPECT indicate an increased risk of PE recurrence.
Patients and methods
Patients
We retrospectively followed all 227 patients diagnosedwith PEwho
had undergone at least 2 examinations with V/P SPECT during
2005–2007 at Lund University Hospital, Lund, Sweden. The follow-up
V/P SPECT had been performed routinely in all these patients.
All patientswere evaluated for risk factors forVTE such asmalignancy,
inflammatory bowel disease, smoking, pregnancy or hormonal therapy,
surgery or immobilisation within the previous 3 months, and hereditary
coagulation defects. Right ventricular strain was evaluated with
echocardiography in 81 (36%) patients, and 45 patients underwent
MDCT in addition to V/P SPECT.
V/P SPECT examinations
PE was quantified by counting segments or subsegments showing
complete or relativemismatch, and expressing thisfigure in % of the total
lung parenchyma [16]. A segmental reduction or a sub-segmental total
deficiency of function was attributed 1 point, and segmental total
deficiency 2 points. According to our charts each lung comprises 9
segments, representing 18 points. Mismatch defects were expressed
as mismatch points, which after division by 36 give the fraction of the
lung that is embolised. All regions with ventilation or perfusion defects
were calculated in order to estimate the reduction in total lung function.
However, quantification of PE is somewhat imprecise as one segment
may contain one as well as two subsegments. Nevertheless quantifica-
tion may provide a useful “rule of thumb” to define an initial treatment
period which can then be confirmed using follow-up V/P SPECT.
Recurrent PE was defined as a new objectively confirmed diagnosis
of symptomatic PE after the second V/P SPECT examination.Table 2
Outcome variables in 227 patients with pulmonary embolism (PE) undergoing 2 examinations
and in subgroups of patients withminor (b20% perfusion defect on SPECT), medium (20-50% pe
treated PE. Patients treated with thrombolysis are shown separately. Mean±SD or n(%).
All patients n=227 Minor PE n=86 Medium
Months of follow-up 47±24 47±24 48±25
Months to second V/P SPECT 7.4±6.8 8.2±7.4 6.2±5.9
Resolution of PE at second V/P SPECT 76 (33) 45 (52) 29 (30)
Recurrent PE after second V/P SPECT 37 (16) 7 (8) 23(23)
Death 59 (26) 17 (20) 33 (33)
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Results are given asmean±SD. Differences over timewithin groups
were evaluated with Wilcoxon´s signed rank test and differences be-
tween groups were evaluated with the Mann–Whitney U-test and the
Chi-square test. Factors that differed between subjects with andwithout
recurrent PE were entered into a multivariate regression analysis.
P-values b0.05 were considered as significant. Kaplan-Meier Survival
Analysis was used to estimate recurrence of PE during follow up.
The study was approved by the Ethical Committee at the University
of Lund. Informed consent was obtained from all subjects.
Results
Patients were categorised according to PE extent: minor PE (b20%
perfusion defect on SPECT, n=86), medium PE (20-50% perfusion
defect on SPECT, n=99), or major PE (>50% perfusion defect on
SPECT, n=42). Background data for the whole patient sample is
shown in Table 1.
Risk factors for venous thromboembolism (VTE) were present in 79
(35%) patients; prior VTE in 49 (22%), and active malignancy in
51(24%). Hereditary coagulation defects were evaluated in 67 (30%) pa-
tients, and could be documented in 22 (33%) of these. Echocardiography
was performed on 75 patients, of whom 39(17%) showed right ventricu-
lar strain. All patients with PE were treated with anticoagulant therapy
for 7.5±4.0 months. Thrombolytic treatment was given in the acute
stage to 16 patients with major PE aged 61±11 years.with ventilation / perfusion (V/P) lung scintigraphywith tomographic (SPECT) technique,
rfusion defect on SPECT), ormajor (>50% perfusion defect on SPECT) with conventionally
PE n=99 Major PE no thrombolysis, n=26 Major PE with thrombolysis, n=16
48±24 47±24
6.5±0.7
2 (5) 0(0)
5 (19) 2 (12)
9 (21) 0(0)
lation/perfusion scintigraphy (V/PSPECT) for follow-up and prediction
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3A. Alhadad et al. / Thrombosis Research xxx (2012) xxx–xxxAt the second V/P SPECT examination, complete resolution of per-
fusion defects had occurred in 45 (52%) of patients with minor PE
after 8.2±7.4 months, in 29 (29%) of patients with medium PE
after 6.2±5.9 months, and in 2(5%) of patients with major PE after
6.5±0.7 months (Table 2).
During 47±24 months of follow up 59 patients (26 %) died and
37(16 %) suffered recurrent PE after the second V/P SPECT examination
(Table 2, Figs. 1–2). Only four of these 37 patients had ongoing therapeu-
tic anticoagulation. Seventeen (20%) of the deaths and7 (8%) of the recur-
rences occurred in the groupwithminor PE, 33 (33%) of the deaths and23
(23%) of the recurrences in the group with medium PE, 9 (21%) of the
deaths, and 5 (19%) of the recurrences in the group with major PE
(Table 2).
Among the 37 patients experiencing recurrent PE after the second
V/P SPECT examination, 34 (92%) had exhibited residual perfusionFig. 2. Results of ventilation / perfusion (V/P) lung scintigraphy with tomographic (SPECT)
and at a later clinical recurrence of PE. Frontal (2a) and sagittal (2b) slices shown.
Please cite this article as: Alhadad A, et al, The value of tomographic venti
of recurrence in pulmonary embolism, Thromb Res (2012), http://dx.doi.odefects at this investigation (Figs. 1–2). Recurrence of PE was also
predicted by advanced age and female gender (Table 3). Inmultivariate
regression analysis, however, recurrence of PE after the second V/P
SPECT examinationwas only predicted by age (p=0.0013) and residual
perfusion defect (p=0.0039, Table 4). The extension of perfusion defect
on V/P SPECT examination in 227 patientswith PE at diagnosis, after 3, 6
and >6 months during ongoing anticoagulant therapy is shown in
Fig. 3.
Discussion
We found that complete resolution of PE was common (52%), espe-
cially in patients with minor PE, whereas residual perfusion defects
were widespread in patients with medium and major PE;71% and 95%
respectively after 6.5±0.7 months.technique in a patient with major pulmonary embolism (PE) initially, after treatment,
lation/perfusion scintigraphy (V/PSPECT) for follow-up and prediction
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Table 3
Factors predicting recurrence of pulmonary embolism (PE) after second examinationwith
ventilation / perfusion (VP) lung scintigraphywith tomographic (SPECT) technique in 227
PE patients. Mean±SD or n(%).
With
recurrence,
n=37
Without
recurrence,
n=190
P-value
Age (years) 71±16 62±17 b0.0001
Gender M/F 10/27 84/106 0.05
Prior VTE (n[%]) 8 (22) 42 (22) 0.95
Malignancy (n[%]) 7 (19) 44 (23) 0.63
Blood pressure (BP, mmHg) 136±20/
81±11
139±23/
80±13
0.59/
0.14
Residual perfusion defect
at second SPECT
34 (92) 117 (62) 0.0004
Prior surgery/immobility 1 (3) 23 (12) 0.088
Autoimmune disease /steroid therapy 6 (16) 29 (15) 0.88
Pregnancy/hormonal therapy 1 (3) 14 (7) 0.29
Completion of anticoagulant therapy at
second SPECT
21 (57) 121 (64) 0.43
Fig. 3. The extension (%) of perfusion defect on ventilation / perfusion (VP) lung scintigraphy
with tomographic (SPECT) technique in 227 patients with pulmonary embolism (PE) at
diagnosis, and after 3 (n=117), 6(n=44) and >6 months (n=66) during ongoing anti-
coagulant therapy.
4 A. Alhadad et al. / Thrombosis Research xxx (2012) xxx–xxxRegarding minor PE, our results are in agreement with recently
published data from a prospective study showing that already after
2 weeks of treatment, 43% patients with PE had normalised perfusion
[16]. These findings are also consistent with earlier observations
[17,18]. In the study by Begic et al. [16] patients were also examined
after 3 and 6 months as these time intervals are often used for antico-
agulant treatment after venous thromboembolism. Interestingly, on
examination with V/P SPECT 70% of patients in this study showed no
perfusion defects after 3 months and patients who did not improve
after 3 months showed a tendency to develop chronic PE [16]. Our re-
sults are consistent with these findings particularly in patients with
minor PE. On the other hand, Wartsky et al. [19] showed higher preva-
lence of residual perfusion defects at 3 months. Miniati et al. [20]
reported normalised perfusion in 65% of patients after 1 year in patients
who survived extensive PE.
Patients with PE are currently recommended at least 6 months of
anticoagulation treatment in current guidelines both from Europe and
USA [8,9,21]. Whether a strategy of follow-up of PE patients with V/P
SPECT and cessation of treatment after documented resolution of PE is
feasible and safe needs to be evaluated in a properly randomised trial.
Some patients with major PE in this study were treated with
thrombolysis, which facilitated early resolution of PE. Evaluation of PE
resolution both in early and later stages after thrombolysis is another
field in which V/P SPECT should be evaluated in a separate prospective
setting. When evaluating risk for recurrent deep venous thrombosis
(DVT), residual thrombosis detected by phlebography or ultrasound
has been shown to be a prognostic factor, but only in patients without
thrombosis predisposing factors [22–24].
In our study of patientswith PE using repeatedV/P SPECT,we had the
opportunity to evaluatewhether signs of residual PEwere an indicator of
possible PE recurrence and found that residual perfusion defects were
present at the second SPECT examination in 34 (92%) of the 37 patients
experiencing recurrent PE.
When evaluating factors affecting the risk of PE recurrence
anticoagulation treatment must be taken into account. However, asTable 4
Multivariate analysis of factors predicting recurrence of pulmonary embolism (PE) after
second examinationwith ventilation / perfusion (VP) lung scintigraphywith tomographic
(SPECT) technique in 227 PE patients. Mean±SD or n(%).
Significance
(p value)
Odds
ratio
(OR)
95% CI for
or lower
95% CI for
or upper
Age (years) 0.0013 1.083 1.031 1.137
Gender M/F 0.1966 0.543 0.215 1.372
Residual perfusion defect at
second V/P SPECT
0.0039 10.578 2.128 52.575
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as this was not a controlled study, this variable is difficult to evaluate.
As a precaution, cliniciansmay choose to recommend an extended dura-
tion of anticoagulation if a follow-up V/P SPECT shows residual perfusion
defects. No formal guidelines on treatment duration in relation to V/P
SPECT results existed in our department at the time of the study,
however, only four patients experienced recurrent PE during ongoing
therapeutic anticoagulation.
Owing to its retrospective nature, this study has several other limita-
tions; for example the fact that cardiopulmonary comorbidity was
poorly documented might have complicated the analysis. None of the
patients that underwent two V/P SPECT examinations were lost to
follow-up, but the study did not include patients with PE who died be-
fore the second examination or patients who failed to attend the second
examination. Although current clinical practice at the department during
the study period included follow-up of PE with repeat V/P SPECT exam-
inations, cliniciansmay also have judged follow-up unnecessary in some
cases. A total of around 300 V/P SPECT examinations on PE patients are
performed yearly at the department, meaning that 227×2=454 of
around 900 V/P SPECT examinations performed during the period have
been studied. Our aims were therefore possible to evaluate in only
about a third of all PE patients during the study period.
In conclusion, complete resolution of PE was common in patients
with minor PE, whereas residual perfusion defects were widespread
in patients with medium and major PE. PE patients with persistent
perfusion defects on follow-up V/P SPECT have a high risk of PE
recurrence.
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